Gts Securities LLC Annovis Bio, Inc. Put Options Transaction History

Gts Securities LLC

3 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 14, 2024	SELL	$4.82 - $18.01 $136,406 - $509,683	-28,300 Reduced 41.31%	40,200 $231,000
Q1 2024 May 15, 2024	BUY	$8.47 - $18.93 $482,790 - $1.08 Million	57,000 Added 495.65%	68,500 $815,000
Q4 2023 Feb 14, 2024	BUY	$5.55 - $19.62 $63,825 - $225,630	11,500 New	11,500 $215,000

1.17M

229K

934K

Ticker ANVS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 8,163,920
Market Cap $46.2M
Description
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...

Get notified when there are updates to the investment portfolio of Gts Securities LLC, based on Form 13F filings with the SEC.

Stay updated on Gts Securities LLC with notifications on news.